On-Demand Webinar

Building IND-Ready and Investor-Ready Development Programs

Learn how emerging biotechs can build IND-ready, investor-ready development programs using Totality of Evidence, NAMs,…

CertaraJune 15, 2026

Poster

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…

CertaraJune 9, 2026

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

CertaraJune 9, 2026

Blog

Beyond compliance: What ICH M15 means for the future of drug development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

CertaraJune 9, 2026

Publication

Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment

Explore how ER upadacitinib formulations met 80–125% bioequivalence criteria under fasting and fed conditions using…

CertaraJune 1, 2026

Publication

Effect of High-Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric-Coated Capsules in Healthy Chinese Subjects

Discover how high-fat meal reduces lansoprazole exposure by up to 61% in a bioequivalence study…

CertaraJune 1, 2026

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-BodnarMay 28, 2026

Publication

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

CertaraMay 21, 2026

On-Demand Webinar

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

Learn how Phoenix NLME and RsNLME support advanced PK/PD workflows and complex pharmacometric modeling through…

CertaraMay 20, 2026

Publication

The pharmacokinetics/pharmacodynamics index of high-dose tigecycline in patients with carbapenem-resistant Enterobacterales bloodstream infection: a prospective study

Learn how prospective study identifies AUC/MIC ≥ 9.90 as a PK/PD target for high-dose tigecycline…

CertaraMay 20, 2026

Clinical Pharmacology

Building IND-Ready and Investor-Ready Development Programs

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond compliance: What ICH M15 means for the future of drug development

Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment

Effect of High-Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric-Coated Capsules in Healthy Chinese Subjects

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

Pharmacometrics Under Pressure Part 3: The Wall: When the Model Gets Harder Than Planned

The pharmacokinetics/pharmacodynamics index of high-dose tigecycline in patients with carbapenem-resistant Enterobacterales bloodstream infection: a prospective study

Newsletter sign up

Quick links

Solutions

Contact